<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-L8N8IEPG</identifier><date>2022</date><creator>Arko, Rozala</creator><creator>Boc, Marko</creator><relation>documents/doc/L/URN_NBN_SI_doc-L8N8IEPG_001.pdf</relation><relation>documents/doc/L/URN_NBN_SI_doc-L8N8IEPG_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 111-112</format><identifier identifier_type="COBISSID_HOST">102349571</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-L8N8IEPG</identifier><language>slv</language><publisher publisher_location="Ljubljana">Katedra za onkologijo</publisher><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Sekcija za internistično onkologijo</publisher><source>Melanom in nemelanomski kožni raki</source><rights>InC</rights><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">melanom</subject><subject language_type_id="slv">rak kože</subject><title>Elektronski vir</title><title>Metastatski maligni melanom s prisotno BRAF mutacijo: klinični primer zdravljenja z BRAF in MEK zaviralci</title><title>Treatment of metastatic malignant melanoma with BRAF and MEK inhibitors: Case report</title></Record>